Alector is a clinical stage biopharmaceutical company developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. Co.'s product candidate, AL001, modulates progranulin (PRGN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. AL101, Co.'s second product candidate in its PGRN portfolio, is designed to treat people suffering from more prevalent neurodegenerative diseases. AL003 is Co.'s second therapeutic candidate designed to treat patients with Alzheimer's disease. AL044 is Co.'s therapeutic candidate for neurodegeneration. The ALEC YTD return is shown above.
The YTD Return on the ALEC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ALEC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ALEC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|